Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S. Davids, Robert J. Soiffer, Haesook T. Kim et al.|New England Journal of Medicine|2016Cited by 595
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b studyMatthew S. Davids, Jennifer R. Brown, Haesook T. Kim et al.|The Lancet Haematology|2018Cited by 115
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S. Davids, Philippe Armand, Haesook T. Kim et al.|Blood|2020Cited by 98
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|The Lancet Haematology|2019Cited by 72
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S. Garcia, Robert J. Soiffer, Scott J. Rodig et al.|Blood|2022Cited by 51